NEW YORK, NY – [Insert Date] – In a landmark development for assistive technology and rehabilitation, Wandercraft, a leading innovator in robotic exoskeletons, has officially launched the U.S. commercial availability of Eve, its revolutionary self-balancing personal exoskeleton. This pivotal announcement ushers in a new era of hands-free upright mobility for eligible adults living with spinal cord injuries (SCI) across all neurological levels, significantly expanding access to advanced rehabilitative care and personal independence.
Eve, heralded as the world’s first FDA-cleared self-balancing personal exoskeleton, represents a monumental leap forward from traditional mobility aids. Unlike its predecessors that often necessitate the use of crutches or walkers for stability, Eve leverages sophisticated physical AI to maintain balance independently, freeing users’ hands for a myriad of daily activities that were once challenging or impossible while upright. This innovative design allows individuals to stand, walk, and interact with their environment in an entirely new, unencumbered way, fostering greater autonomy and an improved quality of life.
A Journey to Commercialization: Chronology and Development
The commercial launch of Eve is the culmination of years of intensive research, development, and rigorous testing by Wandercraft. Founded with a vision to revolutionize human mobility through advanced robotics, the company has consistently pushed the boundaries of what’s possible in assistive technology. Their journey began with the development of the Atalante X, a rehabilitation exoskeleton used in clinical settings, which laid the groundwork for the more personalized and self-balancing capabilities now embodied in Eve. This progression reflects a deep commitment to addressing the unmet needs of individuals with mobility impairments.
The path to U.S. commercialization involved navigating the stringent regulatory landscape of the Food and Drug Administration (FDA). Wandercraft’s comprehensive submission included extensive safety data, robust clinical evidence, and meticulous usability testing, demonstrating Eve’s efficacy and safety across a broad spectrum of spinal cord injury levels. The FDA clearance was not merely a regulatory hurdle; it was a validation of Eve’s groundbreaking design and its potential to safely empower users. This regulatory milestone was particularly significant because it cleared Eve without restrictions based on the neurological level of spinal cord injury, a crucial differentiator that dramatically broadens the potential user population compared to previously available exoskeletons.
Following FDA clearance, Wandercraft meticulously established the necessary infrastructure to support Eve’s commercial rollout. This involved forging strategic partnerships, developing a comprehensive user evaluation and training program, and setting up a dedicated support system to guide individuals through the entire process—from initial inquiry to ongoing maintenance. The company’s focus extended beyond just the technology, emphasizing a holistic approach to user integration and sustained support, ensuring that the transition from clinical trials to personal use is as seamless and effective as possible. The current launch marks the critical transition from theoretical potential to tangible reality, making this life-changing technology accessible to those who need it most.
Unpacking Eve’s Innovation: Supporting Data and Technology
Eve’s distinct advantage lies in its cutting-edge self-balancing technology, powered by advanced physical AI. This proprietary system differentiates Eve fundamentally from other exoskeletons on the market. While many existing devices require users to rely on external supports like crutches or walkers for stability, thereby occupying their hands, Eve intelligently senses and adjusts to maintain equilibrium autonomously. This capability liberates users’ hands, enabling them to perform a vast array of daily tasks that were previously challenging or impossible while upright. Imagine reaching for items on a high shelf, carrying groceries, preparing meals, opening doors, or even engaging in a handshake—all while standing and moving with unprecedented freedom. This hands-free functionality not only enhances physical independence but also significantly boosts confidence and fosters greater social interaction.
Broadened Eligibility and Clinical Evidence
One of the most profound aspects of Eve’s FDA clearance is its unprecedented eligibility criteria. Unlike prior exoskeletons that often imposed restrictions based on the specific neurological level of spinal cord injury, Eve is cleared for adults with SCI at any level, provided they can safely operate the device’s controller and have no contraindications listed in the User Manual. This inclusive approach is a testament to the breadth and depth of the safety data, clinical evidence, and usability testing that Wandercraft diligently compiled and submitted to the FDA. The company’s rigorous development process ensured that Eve’s design and control mechanisms are adaptable and safe for a much wider user base, breaking down barriers that previously limited access to such advanced mobility solutions. This expansion of eligibility is a monumental step towards ensuring that more individuals can benefit from the transformative potential of exoskeleton technology.
Research Validating Personal Use
The commercial launch of Eve is underpinned by robust peer-reviewed research, providing critical evidence for its safety, efficacy, and suitability for personal use. These studies have been instrumental in validating the device’s capabilities and informing the comprehensive training protocols now in place.
A significant study, published in the prestigious Journal of Visualized Experiments (JoVE), focused on how individuals with tetraplegia and high paraplegia, alongside their companions, could be trained to proficiently use a self-balancing exoskeleton for personal, everyday activities. Conducted at renowned institutions such as Kessler Foundation and the James J. Peters VA Medical Center, the research yielded highly encouraging results. Among the first 16 participants who completed the rigorous protocol, all successfully achieved the study’s performance goals for key mobility assessments, including the Timed Up and Go test and the 6-Minute Walk Test. Furthermore, 15 participants met the demanding donning goal after just four training sessions, and every participant achieved the doffing goal, demonstrating the device’s intuitive design and the effectiveness of the training program. Crucially, the researchers reported no serious adverse events among the participants who completed the protocol, underscoring Eve’s high safety profile.
Complementing these findings, additional research presented at the Academy of Spinal Cord Injury Professionals (ASCIP) Annual Meeting in Salt Lake City further reinforced Eve’s capabilities. This study, which analyzed data from the first 16 participant pairs in Wandercraft’s pivotal trial at the James J. Peters VA Medical Center and Kessler Foundation, confirmed that Eve effectively supported safe, hands-free assisted walking for individuals with spinal cord injury, maintaining an impressively low adverse-event rate. Participants in this study also demonstrated the ability to perform a variety of key mobility tasks and activities of daily living (ADLs) with high perceived safety, remarkable user satisfaction, and an ease of training that exceeded expectations.
Dr. Gail Forrest, PhD, who serves as the director of the Tim and Caroline Reynolds Center for Spinal Stimulation at Kessler Foundation, emphasized the profound significance of this research. "What is important about this work is that we evaluated more than whether someone could stand or walk in an exoskeleton," Dr. Forrest stated. "We examined whether people with high-level spinal cord injuries and their companions could learn to use a self-balancing exoskeleton and perform functional tasks relevant to personal use. Commercial availability is an important next step toward translating that clinical work into carefully supported use in everyday life." Her comments highlight the critical shift from controlled clinical environments to the practical realities of daily living, a transition that Eve is uniquely positioned to facilitate.
Official Responses and Stakeholder Engagement
The U.S. commercial launch of Eve is met with enthusiastic responses from Wandercraft leadership, pioneering users, and a robust network of strategic partners, all underscoring the profound impact this technology is set to have.
Wandercraft’s Vision
Matthieu Masselin, co-founder and CEO of Wandercraft, articulated the company’s long-standing vision now coming to fruition. "FDA clearance showed that Eve was ready to move forward. Today is about making it a reality for the people we built it for," Masselin declared. His statement emphasizes the transition from a technological breakthrough to a tangible solution for individuals. He further elaborated on the company’s commitment beyond product development: "We have spent years developing the robotics, but our breakthroughs only matter when we’re able to better connect people to the world around them. That’s why we built an infrastructure that supports people every step of the way, from evaluation and fitting to reimbursement, training, and ongoing service." This comprehensive support system reflects Wandercraft’s dedication to ensuring successful integration of Eve into users’ lives, addressing the complexities of access, adaptation, and sustained benefit.
User Perspective
The transformative potential of Eve is perhaps best captured by the experiences of its test pilots. Caroline Laubach, a Wandercraft test pilot, shared her personal testimony, resonating deeply with the promise of newfound freedom. "With Eve, being upright isn’t just about standing. It’s about having the freedom to use my hands, move through my home, and connect with people in a new way," Laubach expressed. Her words highlight the qualitative shift in daily life that Eve facilitates, moving beyond mere physical function to encompass emotional and social well-being. "Those everyday moments bring me so much joy. What makes this milestone especially meaningful is knowing that more people will now have the chance to experience Eve for themselves and find that same joy in their own way." Her heartfelt endorsement underscores the personal, life-enriching impact of the technology, transforming routine tasks into moments of profound satisfaction and connection.
Partner Network and Accessibility
Wandercraft has meticulously constructed a multi-faceted access and distribution network to ensure that eligible individuals can navigate the process of obtaining Eve with comprehensive support. This infrastructure is designed to address the intricate challenges associated with specialized medical devices, including clinical evaluation, financial navigation, and personalized training.
At the core of this network is Wandercraft’s dedicated access team, which serves as a crucial resource for users and their care teams. This team assists with understanding benefits, preparing necessary documentation, navigating reimbursement pathways, securing financing, and coordinating with clinicians and payers. This comprehensive approach is vital given the specialized nature of the device and the often-complex healthcare system.
Critically, for individuals who meet specific eligibility and medical necessity requirements, Medicare provides coverage for qualifying personal exoskeletons. These devices are classified as custom-fitted orthoses under HCPCS billing code K1007, though coverage remains subject to individual policy requirements. This established pathway for reimbursement is a significant factor in making Eve accessible to a broader population.
To facilitate widespread distribution and localized support, Wandercraft has partnered exclusively with National Seating & Mobility (NSM) as its Complex Rehabilitation Technology (CRT) distribution partner for Eve. NSM, with its extensive network of over 180 locations across the U.S., will play a pivotal role in supporting clinical evaluations, providing essential education, streamlining access, and ensuring efficient delivery of the device. CRT providers like NSM are indispensable in this process, connecting users with a multidisciplinary team of specialists, including clinicians, Assistive Technology Professionals (ATPs), payers, and other experts involved in complex mobility care. Their expertise is crucial in translating a physician’s prescription into a customized, personal mobility solution.
Further enhancing access and expertise, Good Shepherd Rehabilitation has been designated as a Wandercraft Center of Excellence. Located in Pennsylvania’s Lehigh Valley, Good Shepherd has developed deep-seated expertise through its work with Wandercraft’s Atalante X rehabilitation exoskeleton. As Wandercraft’s exclusive Eve partner in the region, Good Shepherd will expand access at its Hyland Center, offering eligible users and their companions opportunities to learn about and eventually experience the technology firsthand. This regional hub will serve as a beacon for best practices in Eve integration and patient care, with additional access locations anticipated to open across the country in the future.
Recognizing the unique needs of military veterans, USVetServ, a Service-Disabled Veteran-Owned Small Business, has been appointed as an authorized independent distributor for both Eve and Atalante X for the U.S. Department of Veterans Affairs (VA), its medical centers, and other VA facilities nationwide. This partnership ensures that veterans, who often face significant mobility challenges due to service-related injuries, will have dedicated pathways to access this transformative technology.
Far-Reaching Implications and Future Outlook
The commercial launch of Wandercraft’s Eve exoskeleton is far more than just a product release; it represents a paradigm shift with profound implications for individuals with spinal cord injuries, the field of assistive technology, and society at large. Its unique capabilities and broadened accessibility are poised to ignite a new era of independence and inclusion.
Transforming Quality of Life
The most immediate and significant implication of Eve’s availability is its potential to radically transform the quality of life for eligible adults with spinal cord injuries. Hands-free upright mobility offers a spectrum of benefits that extend well beyond mere movement. Physiologically, being able to stand and walk can mitigate numerous secondary complications associated with prolonged sitting, such as pressure sores, bone density loss, poor circulation, and respiratory issues. This can lead to improved overall physical health and reduced healthcare burdens over time.
Psychologically, the ability to stand eye-to-eye with others, to move independently through one’s home or community, and to engage in daily activities without constant reliance on others or external supports can dramatically boost self-esteem, mental well-being, and social confidence. It fosters a sense of normalcy and participation that is often lost after an SCI, empowering individuals to reclaim agency in their lives. The emotional uplift from performing simple, everyday tasks like preparing a meal or giving a hug while standing is immeasurable, contributing significantly to mental health and a more positive outlook.
Advancing Assistive Technology
Eve stands as a testament to the accelerating pace of innovation in assistive technology. Its physical AI-driven self-balancing system is a groundbreaking advancement that sets a new benchmark for exoskeleton development. This innovation is likely to spur further research and development in robotics, AI, and human-machine interfaces, pushing the boundaries of what these devices can achieve. It demonstrates the immense potential for intelligent systems to seamlessly integrate with human physiology, providing intuitive and effective support. The success of Eve could inspire new generations of devices that address a broader range of mobility impairments, paving the way for more personalized and adaptable assistive solutions.
Economic and Healthcare Impact
The broadened eligibility criteria, encompassing individuals with SCI at any neurological level, means a significantly larger addressable market for Eve. This expanded access could lead to greater economies of scale in manufacturing and potentially drive down costs in the long run. Furthermore, the potential for reduced secondary complications due to increased upright mobility could lead to substantial long-term healthcare savings, offsetting some of the initial investment in the device. As more insurance providers recognize the value and medical necessity of such advanced exoskeletons, reimbursement pathways may become more streamlined, further improving accessibility. However, challenges will remain in ensuring equitable access and navigating complex reimbursement landscapes, requiring ongoing advocacy and collaboration among manufacturers, healthcare providers, and policymakers.
A New Era of Inclusion
Ultimately, Eve contributes to a broader societal movement towards greater inclusion and participation for individuals with disabilities. By providing the tools for enhanced independence and engagement, technologies like Eve help dismantle physical barriers and foster a more accessible world. It challenges conventional perceptions of disability, showcasing the power of technology to empower individuals to live full, active, and integrated lives within their communities. The ability to move and interact in an upright, hands-free manner can open doors to new educational, vocational, and social opportunities, enriching not only the lives of users but also the fabric of society.
The Road Ahead
The U.S. commercial launch is an exciting beginning, but the journey for Eve and Wandercraft is ongoing. Future endeavors will likely include expanding the network of access locations across the U.S., continuous research to further refine the technology and explore new applications, and potentially, broader international availability. Ongoing user feedback and clinical data will be crucial for iterative improvements and for demonstrating the long-term benefits of Eve in diverse real-world settings. As the technology evolves and becomes more integrated into daily life, it will undoubtedly shape the future of personal mobility for individuals with spinal cord injuries, embodying the promise of a more independent and connected world.
To learn more about Eve or to request an evaluation, interested individuals are encouraged to visit: https://www.wandercraft.eu/form.
